Symbols

RETA(Delisted)

Reata Pharmaceuticals·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About RETA

Reata Pharmaceuticals, Inc.

A clinical-stage biopharmaceutical company that develops novel therapeutics by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation

Industry

Established Date

Listing Date

05/26/2016

Exchange

NASDAQ Stock Exchange

Full-time Employees

321

Fiscal Year Ends

12-31

Website

www.reatapharma.com

Security Type

Common stock

Office address

5320 Legacy Drive, Plano, TX 75024

Business

Introduction

Reata Pharmaceuticals, Inc. was founded in 2002 in Delaware, USA. The Company is a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing product candidates that modulate the activity of key regulatory proteins involved in mitochondrial function, oxidative stress biology, inflammation, to address the medical needs of patients with a variety of serious or life-threatening diseases. The Company's lead product candidates, bardoxolone methyl and RTA 408, are members of a class of small molecules known as antioxidant inflammatory modulators, or AIM. Bardoxolone methyl is in Phase 2 clinical development of pulmonary hypertension, or polycyclic aromatic hydrocarbons, and treatment of pulmonary hypertension due to interstitial lung disease, or PH-ILD, each of which is a subset of pulmonary hypertension, or PH. Preliminary data on patients with PAH in their Phase 2 trial has been published at the October 2015 Chest Conference In addition, it has completed interactions with the U.S. Food and Drug Administration, or FDA, for this initial data, the FDA has endorsed its initiation of a Phase 3 clinical trial in patients with PAH and connective tissue disease, or CTD-PAH related programs.

Company Financials

EPS

RETA has released its 2023 Q1 earnings. EPS was reported at -1.81, versus the expected -2.42, beating expectations. The chart below visualizes how RETA has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

RETA has released its 2023 Q2 earnings report, with revenue of 22.75M, reflecting a YoY change of 2885.04%, and net profit of 193.00M, showing a YoY change of 362.39%. The Sankey diagram below clearly presents RETA's revenue sources and cost distribution.